SLS · SELLAS Life Sciences Group, Inc.

The thesis

SELLAS Life Sciences is still a one-trial story, and the trial has now moved to its final analysis. The company said on 28 October 2026 that REGAL, the Phase 3 study of galinpepimut-S (GPS) in acute myeloid leukemia (AML), reached its pre-specified 80th event, and that it expects to report preliminary topline overall-survival results "this quarter". That result settles the shares; until it arrives, the evidence does not favour the stock over the S&P 500.

The shares fell on the news. They closed at $10.38 on 28 October 2026, down 14.7% from a $12.17 close the session before, according to market reports. The close is 32.9% below the 52-week high of $15.46, and the three-month price change is 3.7% (adjusted daily closes).

The narrative is accelerating toward a decision: the 28 October 2026 release started database lock and unblinding, and the company has put the readout inside 2026 Q4. SELLAS gave no date for lock, unblinding or topline. The release reports no efficacy data.

Bullish and bearish views on SELLAS Life Sciences Group, Inc.

The bull case on SELLAS Life Sciences Group, Inc. (SLS), in brief: The long wait for event 80 is over. The bear case: The market sold the milestone.

Bull case

• The long wait for event 80 is over. SELLAS reported 78 events on 11 May 2026 and 80 on 28 October 2026, confirming a German report from 21 August 2026 that the company had not backed at the time. Database lock, unblinding and the statistical analysis now follow.
• A readout date has been put on the calendar. The 28 October 2026 release says preliminary topline primary-endpoint results will come "this quarter", so the outcome is due by 31 December 2026.
• The company does not need to raise money to reach the result.
• The CEO frames the upside as category-defining. Angelos Stergiou said on 28 October 2026 that positive results "could position GPS as the first- and best-in-class novel immunotherapeutic option" for certain patients. This is the company's own view, and the trial is open-label with no arm-level data released.

Bear case

• The market sold the milestone. Shares dropped 14.7% on 28 October 2026, the day of the event-80 release, after closing at $12.17 the session before. Gurufocus headlined the move as shares sliding after the milestone.
• The result is binary. A miss on overall survival would remove the main value driver. SLS009, in Phase 2, is the only other clinical asset of scale, and SELLAS has no approved product and 13 employees.
• A short seller values the shares far lower. BMF Capital's 31 August 2026 short report put $3.50 on the shares, against the $10.38 close of 28 October 2026. This is a third party's view.
• Dilution has been heavy. Shares outstanding rose from 153,103,459 on 31 December 2025 to 201,918,874 on 30 June 2026. A positive readout could prompt a new offering; the Q3 report will show whether issuance continued after 30 June 2026.
• Retail enthusiasm is part of the price. Stocktwits described retail sentiment as "extremely bullish" after the 28 October 2026 drop. The shares have also reversed earlier rallies, including the 15% rise on the unconfirmed 21 August 2026 report.

Price setup

SLS closed at $10.38 on 28 October 2026. That is below the $11.49 close of 18 September 2026 that the previous note treated as the lowest recent close. It is also below the $11.00 invalidation level in the previous note, which the 28 October 2026 close breached. The 14-day relative strength index (RSI) was 45.4, neutral, against 34.3 on 18 September 2026.

The 52-week high is $15.46, set on 21 August 2026 on the unconfirmed event-80 report. The shares have since traded between that peak and the current close without holding a rise. The 28 October 2026 session reversed a move that had taken the shares to a $12.17 close.

The wait is now measured in weeks rather than quarters, so price is likely to follow the readout rather than technical levels.

Catalysts, next 30 days

• ~10 November 2026 (est.): Q3 2026 financial report. It updates cash, share count and the REGAL timetable, and shows whether issuance continued after 30 June 2026.
• By 31 December 2026: preliminary topline overall-survival results. The company said "this quarter". This settles the case.

Elapsed catalysts

• Undated, any session: database lock and unblinding. SELLAS said on 28 October 2026 it will proceed with both, with no dates. Announcement of either would signal how close topline is. (passed 9d ago)

What would change the view

The case breaks if REGAL misses its primary overall-survival endpoint, or if topline slips past 2026 Q4 without an explanation. A topline hazard ratio near 1.0 would support the short-seller view. A clear survival benefit with a hazard ratio well below 1.0 would reverse the reading, since the shares would then rest on data rather than anticipation.

On price, a daily close below $9.50 would extend the decline that began on the event-80 release and put the shares in a range they have not closed in since the readout wait began. A new equity offering ahead of topline would also weaken the case.

What it trades with

SLS trades on its own trial calendar. Its moves on 21 August 2026 and 28 October 2026 followed company and trial news. Small-cap biotech sentiment may add noise, but the shares have not moved with a named peer group in the evidence reviewed. The sample of two event-driven sessions is too small to draw a conclusion about wider correlation.